YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 - TransCon CNP NDA submission for achondroplasia planned for Q1 2025 ...

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

The tech company’s prices appear set to undercut the long list of competing telehealth companies that rely on aggressive ...

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...